Genelabs Technologies (GNLB) Collaboration with Novartis on Hepatitis C Drug Development Continues t

[Guest guest]

http://www.streetinsider.com/Corporate+News/Genelabs+Technologies+(GNLB)+Collabo\

ration+with+Novartis+on+Hepatitis+C+Drug+Development+Continues+to+Next+Phase/376\

3685.html

Genelabs Technologies (GNLB) Collaboration with Novartis on Hepatitis C Drug

Development Continues to Next Phase

June 23, 2008 9:20 AM EDT

Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced that its hepatitis C

drug development and commercialization collaboration with Novartis (NYSE: NVG)

is continuing to the next phase.

In September 2006, Genelabs and Novartis entered into a two-year collaboration

to discover and develop certain non-nucleoside inhibitors of the NS5b polymerase

in HCV. Genelabs was responsible for drug discovery research and Novartis is

responsible for development and commercialization. The research phase of the

collaboration was completed on June 2, 2008. Genelabs and Novartis will continue

to hold joint research committee meetings to monitor the progress of compounds

discovered during this phase as they advance.

Additionally, Genelabs has announce that Gilead Sciences (Nasdaq: GILD) has

exercised its right to terminate a similar research collaboration agreement for

nucleoside-based inhibitors for the NS5b HCV polymerase, and will return to

Genelabs all rights to the compounds developed in the program.

Genelabs Technologies, Inc., a biopharmaceutical company, engages in the

discovery and development of infectious disease therapies to improve human

health.

_________________________________________________________________

Earn cashback on your purchases with Live Search - the search that pays you

back!

http://search.live.com/cashback/? & pkw=form=MIJAAF/publ=HMTGL/crea=earncashback